3 Firms Guide Goldman Sachs On Buying Synthon Stake

By Najiyya Budaly

The alternative investment arm of Goldman Sachs said Monday that it plans to buy a majority stake in the drugmaker Synthon from British investment firm BC Partners LLP, in a deal that values the Dutch company at a reported €2 billion ($2.1 billion).